Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

pembrolizumab 45Carboplatin 40Cisplatin 36Paclitaxel 29Nivolumab 24Pemetrexed 24Gemcitabine 23Dexamethasone 21Rituximab 18Ipilimumab 16Cyclophosphamide 15Capecitabine 14Fluorouracil 14Docetaxel 13atezolizumab 13Lenalidomide 12Trastuzumab 12durvalumab 12trastuzumab deruxtecan 12Cytarabine 11daratumumab 11130-nm albumin-bound paclitaxel 10Bevacizumab 10Bortezomib 10Prednisone 10olaparib 10Doxorubicin 9Crizotinib 8Oxaliplatin 8venetoclax 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × apalutamide × Clear all
NCT01946204 2026-06-05

SPARTAN

Aragon Pharmaceuticals, Inc.

Phase 3 Active not recruiting
1,207 enrolled 15 charts 1 FDA
Genitourinary

Prostatic Neoplasms

NCT02489318 2026-06-05

TITAN

Aragon Pharmaceuticals, Inc.

Phase 3 Active not recruiting
1,052 enrolled 13 charts 1 FDA
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡